Document Detail


The effect of growth hormone and IGF-I on clonogenic growth of hematopoietic cells in leukemic patients during active disease and during remission--a preliminary report.
MedLine Citation:
PMID:  8374694     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The number of survivors of childhood leukemia treated with growth hormone for growth retardation is increasing. The debate about the direct or indirect relationship of GH and insulin-like growth factor I (IGF-I) to the occurrence or recurrence of malignancy, especially in the case of GH therapy in patients with leukemia, is still unresolved. We, therefore, studied the effect of GH and IGF-I on bone marrow of patients with acute leukemia (ALL and AML) in diagnosis and recurrence and in chronic leukemia patients (CML) in remission. GH increased blast colony numbers by a mean of 68% and 77% at GH concentrations of 250 and 300 ng/ml, respectively. IGF-I increased blast colony numbers in ALL patients by 50, 93 and 105%, and in AML patients by 33, 58 and 65%, at IGF-I concentrations of 0.05, 0.25 and 0.5 ng/ml, respectively. In 3 CML patients in remission a granulocyte-macrophage colony forming assay did not reveal stimulation of peripheral blood blast colony formation by GH or IGF-I. Our in vitro data (as previously reported) suggest that GH and IGF-I may promote blast cell proliferation, and the supplemental administration of these peptides in leukemia patients in remission must be carefully monitored for early relapse. Additional studies on bone marrow cells of leukemic patients in remission are needed in order to examine the effects of GH and IGF-I on these cells.
Authors:
Z Zadik; Z Estrov; Y Karov; T Hahn; Y Barak
Related Documents :
6510404 - Red cell pyruvate kinase in acute leukemia.
15567454 - Symptomatic venous thromboembolism in acute leukemia. incidence, risk factors, and impa...
10838454 - Diagnosis of granulocytic sarcoma by fine-needle aspiration cytology.
12886244 - Minimal residual disease detection in childhood precursor-b-cell acute lymphoblastic le...
22536774 - When should we measure vitamin d concentration in clinical practice?
21470994 - Presentation of primary adrenal insufficiency in childhood.
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  The Journal of pediatric endocrinology     Volume:  6     ISSN:  0334-018X     ISO Abbreviation:  J Pediatr Endocrinol     Publication Date:    1993 Jan-Mar
Date Detail:
Created Date:  1993-10-19     Completed Date:  1993-10-19     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8510464     Medline TA:  J Pediatr Endocrinol     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  79-83     Citation Subset:  IM    
Affiliation:
Pediatric Endocrine Unit, Kaplan Hospital, Rehovot, Israel.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Bone Marrow / drug effects,  pathology
Cell Division / drug effects
Child
Child, Preschool
Dose-Response Relationship, Drug
Female
Granulocytes / pathology
Growth Disorders / drug therapy
Growth Hormone / pharmacology*,  therapeutic use
Hematopoietic Stem Cells / drug effects,  pathology*
Humans
Infant
Insulin-Like Growth Factor I / pharmacology*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology*
Leukemia, Myeloid, Acute / pathology*
Macrophages / pathology
Male
Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology*
Remission, Spontaneous
Chemical
Reg. No./Substance:
67763-96-6/Insulin-Like Growth Factor I; 9002-72-6/Growth Hormone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Growth hormone (GH) and adult bone remodeling: the potential use of GH in treatment of osteoporosis.
Next Document:  Regulation of myeloid phagocyte development and function by growth hormone: a review.